Study of TSR-033 with an Anti-programmed cell death-1 receptor (PD-1) in participants with Advanced Solid Tumors

Trial Identifier: 213349
Sponsor: Tesaro
Collaborator:
GlaxoSmithKline
Start Date: August 2017
Primary Completion Date: June 2022
Study Completion Date: February 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
France Villejuif cedex, France, 94805
United States, California Los Angeles, California, United States, 90095
United States, California Whittier, California, United States, 90603
United States, Florida Sarasota, Florida, United States, 34232
United States, Florida Tampa, Florida, United States, 33612
United States, Massachusetts Boston, Massachusetts, United States, 02115
United States, Ohio Cleveland, Ohio, United States, 44106
United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina Greenville, South Carolina, United States, 29605
United States, Texas Houston, Texas, United States, 77030
United States, Texas San Antonio, Texas, United States, 78229